NO20001869L - FremgangsmÕte for behandling av Alzheimers sykdom - Google Patents

FremgangsmÕte for behandling av Alzheimers sykdom

Info

Publication number
NO20001869L
NO20001869L NO20001869A NO20001869A NO20001869L NO 20001869 L NO20001869 L NO 20001869L NO 20001869 A NO20001869 A NO 20001869A NO 20001869 A NO20001869 A NO 20001869A NO 20001869 L NO20001869 L NO 20001869L
Authority
NO
Norway
Prior art keywords
alzheimer
disease
procedure
treatment
Prior art date
Application number
NO20001869A
Other languages
English (en)
Other versions
NO20001869D0 (no
Inventor
David Robert Howlett
Davina Elizabeth Mitchell
Original Assignee
Boehringer Mannheim Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharm Corp filed Critical Boehringer Mannheim Pharm Corp
Publication of NO20001869D0 publication Critical patent/NO20001869D0/no
Publication of NO20001869L publication Critical patent/NO20001869L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20001869A 1997-10-15 2000-04-11 FremgangsmÕte for behandling av Alzheimers sykdom NO20001869L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6236697P 1997-10-15 1997-10-15
PCT/US1998/021789 WO1999018794A1 (en) 1997-10-15 1998-10-15 Method for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
NO20001869D0 NO20001869D0 (no) 2000-04-11
NO20001869L true NO20001869L (no) 2000-06-14

Family

ID=22042015

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001869A NO20001869L (no) 1997-10-15 2000-04-11 FremgangsmÕte for behandling av Alzheimers sykdom

Country Status (16)

Country Link
US (1) US6358990B1 (no)
EP (1) EP1024697A4 (no)
JP (1) JP2001519364A (no)
KR (1) KR100573352B1 (no)
CN (1) CN1281334A (no)
AU (1) AU751526B2 (no)
BR (1) BR9814075A (no)
CA (1) CA2305262A1 (no)
HU (1) HUP0100024A3 (no)
IL (1) IL135584A (no)
NO (1) NO20001869L (no)
NZ (1) NZ504419A (no)
PL (1) PL339910A1 (no)
TR (1) TR200001018T2 (no)
WO (1) WO1999018794A1 (no)
ZA (1) ZA989365B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142175A1 (de) * 2001-10-09 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung von ß-Adrenozeptor-Agonisten zur Behandlung von neurodegenerativen Erkrankungen
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
KR101468827B1 (ko) * 2002-06-27 2014-12-03 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
CN1991364A (zh) * 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
WO2008021552A2 (en) * 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US20110046378A1 (en) 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
CN103172643B (zh) * 2011-12-26 2016-03-02 中国医学科学院药物研究所 黄皮咔唑生物碱及其制备方法和其药物组合物与用途
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
KR20160026897A (ko) 2013-06-27 2016-03-09 세다르스-신나이 메디칼 센터 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제
US20230381139A1 (en) * 2020-09-17 2023-11-30 Uti Limited Partnership Methods of treating and/or preventing alzheimer’s disease with r-carvedilol
CN115487297A (zh) * 2021-06-17 2022-12-20 清华大学 治疗神经元蜡样质脂褐质沉积症的方法和药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
EP0275668B1 (en) * 1986-12-17 1992-09-30 Glaxo Group Limited Use of ketone derivatives in the treatment of cognitive disorders
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
JPH0558998A (ja) * 1991-09-06 1993-03-09 Taisho Pharmaceut Co Ltd カルバゾール誘導体
MX9700696A (es) * 1994-07-27 1997-04-30 Sankyo Co Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
FR2724933A1 (fr) * 1994-09-22 1996-03-29 Pf Medicament Nouveaux ethers aromatiques derives d'indoles utiles comme medicaments
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
EP1110945A3 (en) * 1995-05-01 2003-05-07 University Of Pittsburgh Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition

Also Published As

Publication number Publication date
TR200001018T2 (tr) 2000-08-21
NO20001869D0 (no) 2000-04-11
WO1999018794A1 (en) 1999-04-22
EP1024697A4 (en) 2007-05-02
EP1024697A1 (en) 2000-08-09
IL135584A0 (en) 2001-05-20
KR20010031108A (ko) 2001-04-16
AU1089799A (en) 1999-05-03
JP2001519364A (ja) 2001-10-23
BR9814075A (pt) 2000-09-26
KR100573352B1 (ko) 2006-04-25
IL135584A (en) 2005-12-18
ZA989365B (en) 1999-04-15
US6358990B1 (en) 2002-03-19
HUP0100024A3 (en) 2002-12-28
PL339910A1 (en) 2001-01-15
CA2305262A1 (en) 1999-04-22
NZ504419A (en) 2002-11-26
HUP0100024A2 (hu) 2001-07-30
AU751526B2 (en) 2002-08-22
CN1281334A (zh) 2001-01-24

Similar Documents

Publication Publication Date Title
NO20026199L (no) Forbindelser for behandling av Alzheimers sykdom
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
FI962557A0 (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
NO944928D0 (no) Fremgangsmåter for inhibering av Alzheimers sykdom
NO20001869L (no) FremgangsmÕte for behandling av Alzheimers sykdom
EP1043991A4 (en) TREATMENT OF ALZHEIMER DISEASE
NO965377L (no) Indolinonforbindelser for behandling av sykdommer
FI952721L (fi) Aine maksa-sappi-sairauksien hoitamiseksi
NO995221D0 (no) Sulfonamider for behandling av endotelinmedierte sykdommer
FI20000720A7 (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
NO20032007L (no) Radiofarmasöytika for diagnostisering av Alzheimers sykdom
FI953915A0 (fi) Dupuytrenin taudin lievittämiseen
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
NO20010953D0 (no) En fremgangsmÕte for behandling av stafylokokkal sykdom
NO20000771D0 (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
FI982689L (fi) 2-fenyyli-1,2-bentsoisoselenatsol-3(2H)-onin käyttö Alzheimerin taudin käsittelyyn tarkoiettujen farmaseuttisten valmisteiden valmistukseen
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
AU1405899A (en) Treatment for alzheimer's disease
EP1181550A4 (en) METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
NO991158L (no) FremgangsmÕte for behandling av amyotrofisk lateralsklerose
FI952953L (fi) Aineita metabolisten luustosairauksien hoitamiseen
NO961180D0 (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
NO970127D0 (no) Topiske sammensetninger for behandling av hudsykdom